Prozac and Fluoxetine Face Supply Disruptions in French Pharmacies
- Prozac and generic fluoxetine treatments face temporary production difficulties causing supply disruptions across French pharmacies, according to an announcement by the French National Agency for Medicines and Health...
- The regulatory agency has ordered all pharmaceutical laboratories to boost supply capacities by releasing their complete available inventories, including dedicated safety stocks.
- Fluoxetine is prescribed primarily for major depressive episodes, obsessive-compulsive disorders, and bulimia.
Prozac and generic fluoxetine treatments face temporary production difficulties causing supply disruptions across French pharmacies, according to an announcement by the French National Agency for Medicines and Health Products Safety on September 25, 2026. Health authorities expect the supply situation to normalize by mid-October 2026 as industrial manufacturing output resumes.
French Pharmacies Grapple With Prozac and Generic Fluoxetine Shortages
Regulatory Order Deploys Safety Stocks and Export Bans
The regulatory agency has ordered all pharmaceutical laboratories to boost supply capacities by releasing their complete available inventories, including dedicated safety stocks. Distribution controls implemented on September 1, 2026, include strict quantitative quotas alongside a formal export ban to protect domestic supplies of the antidepressant medication.
Critical Care Priorities for Pediatric and Adolescent Patients
Fluoxetine is prescribed primarily for major depressive episodes, obsessive-compulsive disorders, and bulimia. The active ingredient remains the sole antidepressant authorized for treating specific depressive episodes in children starting at eight years of age and in adolescents.
To protect vulnerable patients, the health agency urges healthcare providers to reserve newly initiated treatments strictly for pediatric depressive episodes beginning at age eight and for adolescent care. This prioritization aims to ensure uninterrupted therapeutic continuity for patients who have already established treatment routines.
Incoming Industrial Shipments Aim for Mid-October Normalization
Industrial supply shipments scheduled for release at the end of September 2026 will flow directly into the commercial distribution chain. The agency anticipates that these incoming deliveries will resolve pharmacy shortages and restore standard availability nationwide by mid-October 2026.